Previous 10 | Next 10 |
home / stock / esaly / esaly news
Biologics License Application for Lecanemab Designated for Priority Review by China National Medical Products Administration TOKYO, Feb 28, 2023 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that the Biologics License Application (BLA) for lecanemab (brand name ...
Dissolution of Bracco-Eisai Joint Venture TOKYO, Feb 21, 2023 - (JCN Newswire) - Bracco Imaging S.p.A. and Eisai Co., Ltd. announced today that the joint venture regarding the company Bracco-Eisai Co., Ltd. (Ratio of Shares Held: Bracco 51% Eisai 49%), will be dissolved as of March ...
Eisai Co., Ltd. (ESALF) Q3 2022 Earnings Conference Call February 06, 2023 03:15 AM ET Company Participants Tatsuyuki Yasuno - Senior Vice President, Chief Financial Officer, Chief IR Officer Ivan Cheung - Senior Vice President, Global Alzheimer's Disease Officer, Presiden...
The following slide deck was published by Eisai Co., Ltd. in conjunction with their 2022 Q3 earnings call. For further details see: Eisai Co., Ltd. 2022 Q3 - Results - Earnings Call Presentation
Summary Biogen's business focuses on developing and commercializing drugs aimed at treating patients living with neurological and neurodegenerative diseases. The company's total revenue was $2,508.5 million in the third quarter of 2022, down 9.7% from the previous year. The decline ...
A regulatory failure for one drugmaker often represents a key win for another company. That might be the case in the Alzheimer's disease market after a recent U.S. Food and Drug Administration (FDA) decision. Last week, the FDA issued a complete response letter for Eli Lilly 's (NYSE: L...
Summary Anavex 2-73/blarcamesine at high concentrations in early Alzheimer's disease leads to improvements in cognition and activities of daily living that are largely sustained for 148 weeks in most individuals. Alzheon's ALZ-801 reduces cognitive decline in ApoE4 carriers by about the...
EISAI FILES MARKETING AUTHORIZATION APPLICATION FOR ANTI-AMYLOID-BETA PROTOFIBRIL ANTIBODY LECANEMAB FOR EARLY ALZHEIMER'S DISEASE IN JAPAN PR Newswire TOKYO and CAMBRIDGE, Mass. , Jan. 15, 2023 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo , CEO: ...
You can't blame Biogen (NASDAQ: BIIB) investors if they feel a sense of déjà vu. The company, along with its partner, Japanese drugmaker Eisai (OTC: ESALY) , received U.S. Food and Drug Administration (FDA) approval for Alzheimer's disease drug Leqembi (lecanemab-irmb) l...
The US FDA on Friday granted accelerated approval to Biogen ( NASDAQ: BIIB ) and Eisai's ( OTCPK:ESALY ) Leqembi (lecanemab), just the second biologic medicine ever approved for Alzheimer's disease. The therapy is expected to become available around the week of Jan. 23. It com...
News, Short Squeeze, Breakout and More Instantly...
Eisai Co. Ltd. ADR Company Name:
ESALY Stock Symbol:
OTCMKTS Market:
Eisai's Initiatives for Developing New Medicines for Neglected Tropical Diseases and Malaria and Commitment for Funding to the 3rd Phase of Global Health Innovative Technology Fund Activities TOKYO, May 25, 2023 - (JCN Newswire) - Eisai Co., Ltd. has announced that it will grant a t...
Eisai Delivers New Data and Highlights Continued Progress of Oncology Portfolio and Pipeline at ASCO 2023 TOKYO, May 24, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced today the presentation of research across various types of cancer from its oncology portfolio and pipeline durin...
Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer's Disease TOKYO and CAMBRIDGE, Mass., May 16, 2023 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that Health Canada has accepted a New Drug Submission (NDS) for lecanemab (b...